Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 64.2 kDa.
AF555
Excitation Wavelength: 561 nm
Emission Wavelength: 572 nm
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
5e5 of 293 CAR cells transfected with anti-CD27 Ligand-scFv were stained with 100 μL of 3 μg/mL of Alexa Fluor 555-Labeled Human CD27 Ligand Protein, His Tag (Cat. No. CDL-HA245) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A), Alexa 555 signal was used to evaluate the binding activity (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Cusatuzumab | ARGX-110; JNJ-4550 | Phase 2 Clinical | Argenx Se | Myelodysplastic Syndromes; Neoplasms; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
PRO-1160 | PRO-1160 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Nasopharyngeal Carcinoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
Allogeneic gamma delta T cell therapy(Adicet Bio) | ADI-270 | Phase 2 Clinical | Adicet Bio Inc | Carcinoma, Renal Cell | Details |
CD70 Targeted CAR-T Cells Therapy(UTC Therapeutics) | Phase 2 Clinical | UTC Therapeutics Inc | Solid tumours; Urologic Neoplasms; Lymphoma | Details | |
Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Shanghai Tongji Hospital) | Phase 2 Clinical | Shanghai Tongji Hospital | Lymphoma, B-Cell | Details | |
MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
CTX-131 | CTX-131 | Phase 2 Clinical | Crispr Therapeutics Ag | Lymphoma, B-Cell; Carcinoma, Renal Cell; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Mesothelioma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Uterine Cervical Neoplasms | Details |
GD2/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
SEA-CD70 | SEA-CD70; PF-08046040 | Phase 1 Clinical | Seagen Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
BR-108 | BR-108 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Hematologic Neoplasms; Leukemia | Details |
ARX-305 | ARX-305; NCB-002 | Phase 1 Clinical | Ambrx Inc | Neoplasms | Details |
CD70-CAR-NK Cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Leukemia, Myeloid, Acute; Lymphoma, T-Cell | Details | |
Anti-CD70-CAR-T Cell therapy(First Song Biotechnology) | Phase 1 Clinical | Shanghai First Song Therapeutics Co Ltd | Carcinoma, Renal Cell | Details | |
Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine) | Phase 1 Clinical | The Children'S Hospital, Zhejiang University School Of Medicine | Nephrosis | Details | |
CD70 UCAR T cells Therapy (Nanjing Calmhome Cell and Gene Engineering Institute) | CHT-101; CHT101 | Phase 1 Clinical | Nanjing Calmhome Cell and Gene Engineering Institute Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
Chimeric Antigen Recertor Treatment Targeting CD70(Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, T-Cell | Details | |
CAR T-cell Therapy Directed to CD70(St Jude Children's Research Hospital) | Phase 1 Clinical | St. Jude Children'S Research Hospital | Hematologic Neoplasms; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma | Details | |
CD70-targeted CAR-NKT Cells Therapy (CureGenetics) | CGC729; CGC-729 | Phase 1 Clinical | Suzhou Cure Genetics Biosciences Co Ltd | Solid tumours; Carcinoma, Renal Cell | Details |
CD70-CART(Hrain) | HR010; HR-010 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Renal Cell | Details |
Anti-CD19/CD70 NK cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, B-Cell | Details | |
CD70 CAR-T cell therapy (Chongqing Precision Biotech) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Neoplasms; Genital Neoplasms, Female; Neoplasm Metastasis; Uterine Cervical Neoplasms | Details | |
IMM-40H | IMM-40H; IMM40H | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
ALLO-316 | ALLO-316 | Phase 1 Clinical | Cellectis Sa, Overland Pharmaceuticals (Shanghai) Co Ltd | Carcinoma, Renal Cell; Leukemia, Myeloid, Acute | Details |
CD70 CAR T-cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details | |
C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
CD70-targeted CAR-NKT Cells Therapy(Cure Genetics Biosciences) | CGC738; CGC-738 | Clinical | Suzhou Cure Genetics Biosciences Co Ltd | Carcinoma, Renal Cell | Details |
CD19/CD70 CAR-NK cells therapy (Rongu Biotechnology) | RG-1970 | Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell; Neoplasms | Details |
This web search service is supported by Google Inc.